B. Metzler Seel. Sohn & Co. Holding Ag Keros Therapeutics, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Holding Ag
- $10.1 Trillion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Holding Ag transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Holding Ag holds 16,103 shares of KROS stock, worth $1.08 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,103Holding current value
$1.08 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding KROS
# of Institutions
158Shares Held
27.5MCall Options Held
28.7KPut Options Held
1.8K-
Black Rock Inc. New York, NY2.51MShares$169 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$118 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.6MShares$107 Million0.12% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.53MShares$102 Million8.43% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.27MShares$85.2 Million1.4% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.73B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...